The team at Neuregenix include experienced business managers, scientists and clinicians who have managed £multimillion biomedical and clinical research projects and taken drugs through to the clinic.
The quality of the work provided is based on the experience and qualifications of our scientific staff. All our technical staff undergo a rigorous internal training followed by continuous improvement programs. As a result, we are able to build long-lasting working relationships ensuring the continuity of your projects.
Mr Richard Mansfield
Richard has a strong track record of translational project management and commercial exploitation in other high tech sectors. Before joining Neuregenix, Richard founded and was CTO, COO and CEO of Scyron Ltd, until its successful acquisition by a multi-national company in 2009.
Professor Ann Logan
Ann is Scientific Director at Neuregenix and also Professor of Molecular Neuroscience at the University of Birmingham. She is a world leader in neurotrauma research. At the University of Birmingham she leads a £1.8 million NIHR/MRC/BBSRC-funded regenerative neurobiology research programme with close links to clinical stakeholders at the adjacent Queen Elizabeth Hospital. Ann has <30 years experience in navigating large and small translational projects from conception, through pre-clinical testing to clinical trial.